Abstract: Endometrial receptivity plays a key role in embryo implantation and normal pregnancy maintenance. Its injury or abnormality will lead to pregnancy diseases such as recurrent implantation failure（RIF）. In this study, bioinformatics methods were used to identify the potential regulatory targets and therapeutic drugs for impaired endometrial receptivity in patients with RIF. The currently existing datasets of women endometrium in window period with/without RIF were retrieved and downloaded from GEO database. Total of 95 differentially expressed mRNAs were identified from 246 samples in 6 groups of datasets by RobustRankAggreg method. It was found that 10 hub genes such as EGR1 and FOS are potential regulators of RIF, and pathways such as regulation of inflammatory response, response to ischemia are involved RIF progress. 3 differentially expressed microRNAs were identified from 85 samples in 2 groups of datasets. Further analysis of mRNA-microRNA regulatory network revealed that miR-449-5 p and miR-186-5 p may participated in RIF by regulate multiple differentially expressed mRNAs. Finally, the anti-inflammatory drugs amprilose and dapsone may be drug candidates for RIF therapy through the drug analysis of CMap. This study provides clues for understanding the mechanism of endometrial receptivity and improving the success rate of assisted reproductive technology.